CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The research sought to evaluate responses based on the availability of images, imaging reports, and clinician assessment.
Dr. Janet L. Espirito’s recently conducted research on the potential for real-world data to assess therapeutic responses in patients with mNSCLC has revealed promising results, indicating the feasibility and applicability of real-world data in this context. The study, which involved collaboration with the Friends of Cancer Research Organization and several electronic health record data partners, marked a significant milestone in the utilization of real-world datasets for therapeutic response assessment.
Key Points:
- The research was aimed at identifying methods to evaluate real-world responses to chemotherapy in patients with mNSCLC, leveraging real-world data.
- A uniform protocol and statistical analysis plan were formulated in collaboration with seven electronic health record data partners.
Additional Points:
- The study revealed consistent findings across all data sources in real-world response rates despite the variation in data sources.
- Although the availability of raw images was inconsistent across data partners, imaging reports and clinician assessment of response were consistently available.
- This research underscores the potential for real-world data to assess therapeutic response.
Conclusion:
- The findings suggest that real-world data can reliably be used for assessing therapeutic response, and could help formulate best practices and recommendations for this approach. Further exploration of real-world data can continue to be utilized to support decision making.
Pulmonology Latest Posts
- When Should I Give Corticosteroids to My Patient with Pneumocystis Pneumonia?
- How Does Climate Change Impact Our Patients?
- Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall
- Corticosteroids: Giving and Taking Away
“I think certainly real-world data is growing in interest and importance in terms of being able to understand effectiveness of therapies in larger populations outside of clinical trials…”
Janet L. Espirito, PharmD
Senior Medical Director
Ontada
